Publicaciones (42) Publicaciones de David Santamaría Velilla

2024

  1. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

    Nature, Vol. 629, Núm. 8013, pp. 919-926

  2. Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node

    Molecular Oncology, Vol. 18, Núm. 6, pp. 1355-1377

2023

  1. Reuniting philosophy and science to advance cancer research

    Biological Reviews, Vol. 98, Núm. 5, pp. 1668-1686

2022

  1. Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer

    Clinical Cancer Research, Vol. 28, Núm. 8, pp. 1640-1650

  2. How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC)

    Cancer Treatment Reviews, Vol. 103

2021

  1. Gene expression profiling as a potential tool for precision oncology in non-small cell lung cancer

    Cancers, Vol. 13, Núm. 19

  2. RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression

    Cancer Cell

  3. Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer

    Trends in Cancer, Vol. 7, Núm. 5, pp. 410-429

2020

  1. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma

    JCI Insight, Vol. 5, Núm. 15

  2. Meeting report – first discoidin domain receptors meeting

    Journal of Cell Science

  3. Squamous differentiation requires G2/mitosis slippage to avoid apoptosis

    Cell Death and Differentiation, Vol. 27, Núm. 8, pp. 2451-2467

  4. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 117, Núm. 39, pp. 24415-24426

2019

  1. Myc stimulates cell cycle progression through the activation of Cdk1 and phosphorylation of p27

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. A putative role for Discoidin Domain Receptor 1 in cancer chemoresistance

    Cell Adhesion and Migration, Vol. 12, Núm. 4, pp. 394-397

  2. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

    Cell, Vol. 172, Núm. 4, pp. 857-868.e15

  3. Molecular determinants of acquired resistance to BRAF inhibition in human lung cancer

    Lung Cancer

2017

  1. A Braf kinase-inactive mutant induces lung adenocarcinoma

    Nature, Vol. 548, Núm. 7666, pp. 239-243

  2. In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma

    Oncogene, Vol. 36, Núm. 16, pp. 2309-2318

2016

  1. An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia

    Oncotarget, Vol. 7, Núm. 32, pp. 51163-51173

  2. Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma

    Nature Medicine, Vol. 22, Núm. 3, pp. 270-277